This study investigated whether the use of pharmacotherapies specifically targeting obesity 7 can help reduce symptoms and physical limitations in this HFpEF phenotype
A comprehensive literature search was performed in PubMed, Web of Science, Embase, and Scopus from inception to October 2025 using the keywords tirzepatide, GLP-1/GIP receptor agonist, obstructive sleep apnea, and obesity. Priority was given to randomized controlled trials, major observational studies, and relevant mechanistic research
it is not yet MHRA-licensed in the UK
Thats a big deal, especially when you think about obesity as a risk factor for so many chronic illnesses. Drawing on nationally representative U.S
One study has found that the primary reason patients drop out of GLP-1 medication programs, is due to the side effects caused by the drugs
One patient I spoke to had been using compounded GLP-1s to manage her lupus symptoms because of cost issues and was increasing her dose without consulting her doctor whenever she felt its effects plateau